Table 1.
Demographic and baseline characteristics of treated patients
| OROS® hydromorphone (n=336) | |
|---|---|
| Mean ± SD age, years | 48.2 ± 11.7 |
| Sex, n (%) | |
| Male | 151 (45) |
| Female | 185 (55) |
| Mean ± SD height (cm) | 170.6 ± 11.0 |
| Mean ± SD weight (kg) | 81.4 ± 22.0 |
| Type of pain, n (%) | |
| Sympathetic | 16 (5) |
| Musculoskeletal | 174 (52) |
| Neuropathic | 134 (40) |
| Other | 12 (4) |
| Location of pain, n (%) | |
| Back | 195 (58) |
| Limbs | 179 (53) |
| Face/head/neck | 64 (19) |
| Torso | 57 (17) |
| Previous opioid medication, n (%) | |
| Codeine | 10 (3) |
| Fentanyl | 22 (7) |
| Hydrocodone | 46 (14) |
| Hydromorphone | 23 (7) |
| Meperidine | 1 (0.3) |
| Methadone | 21 (6) |
| Morphine | 72 (22) |
| Oxycodone | 133 (40) |
| Propoxyphene | 6 (2) |
| Mean daily opioid requirement (mg)* | 154.5 |
*Morphine equivalent at end of stabilisation phase.